Blood cell markers to predict response in metastatic castration resistant prostate cancer
Studies blood tumor cells and biomarkers in men with advanced prostate cancer on hormonal treatment.
Key facts
- Who runs it
- Duke University
- Where
- Durham, Madison, and New York, United StatesSee the 3 sites
- Trial code
- Registry title
- ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 13 May 2024
- Expected to end
- Apr 2027
- Type of study
- Observational
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. Their cancer must have progressed on a strong hormone-blocking drug, and they must be about to start another.
- Age
- Older than 18 years.
- Sex
- Men only.
- Disease stage
- Prostate adenocarcinoma that has spread (metastatic), seen on CT, MRI or PET scans. Testosterone must be at castrate level (below 50 ng/dl) or the man must be on ongoing androgen deprivation therapy. PSA must be rising, with at least 2 rises 2 weeks apart and a minimum PSA of 1.0 ng/dl.
- Earlier treatment
- The cancer must have progressed on one potent androgen receptor inhibitor (darolutamide, abiraterone, enzalutamide or apalutamide, or a combination). Enzalutamide and/or abiraterone acetate or another potent androgen receptor inhibitor must be planned within the next 6 weeks.
Main reasons for not taking part
- Pure small cell or neuroendocrine prostate tumor
- Another illness, including active stage IV cancer, that would make blood draws difficult, as judged by the investigators
- Unwilling to be followed over time for repeated blood tests
- Life expectancy under 6 months
- Planned combination with radiation or other drug treatments besides ADT and bone health agents
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients will be eligible for inclusion in this study only if all of the following criteria apply:
- Histologically confirmed diagnosis of adenocarcinoma of the prostate. Patients with pure small cell/neuroendocrine tumors of the prostate are not permitted
- Radiographic evidence of metastatic disease by CT, MRI, or PET imaging
- Prior documented disease progression on one potent AR inhibitor (darolutamide, abiraterone, enzalutamide, or apalutamide or combinations of these) in any disease setting (mHSPC, nmCRPC, mCRPC) based on sequential PSA rises or radiographic progression
- Planned therapy with either standard of care enzalutamide and/or abiraterone acetate or another potent AR inhibitor (darolutamide, apalutamide if available) within the coming 6 weeks
- Castrate levels of testosterone (<50 ng/dl) at most recent assessment and/or documented ongoing Androgen Deprivation Therapy
- Evidence of disease progression based on a rising PSA on or following most recent therapy as evidenced by the following:; Consecutive PSA rises at least 2 weeks apart; Minimum PSA of 1.0 ng/dl prior to entry
- Age > 18 years
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Planned combination therapy with radiation or other systemic therapies other than ADT and bone health agents
- History of intercurrent or past medical or psychiatric illness including active stage IV malignancy that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s)
- A patient will not be eligible for inclusion in this study if any of the following criteria apply:
- Unwillingness to be followed longitudinally for serial CTC biomarker studies
- Life expectancy < 6 months
Where in United States
- Duke University Medical CenterDurham, United StatesContact: Julia Hurrelbrink, RN, BSNTaking people
- University of Wisconsin - MadisonMadison, United StatesContact: Laura RuelleTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Dana Rathkopf, MDTaking people
About the trial
What the trial wants to find out
This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients respond to the cancer treatment they receive. As tumors grow and begin to spread, they may release cells into patients' bloodstream. These cells are called "circulating tumor cells", or CTCs. CTCs can be used to look for differences in "biomarkers" (genes or proteins that may change based on how a person is or is not responding to treatment). The purpose of this research study is to learn whether scientists can use biomarkers from CTCs to predict which tumors will respond to certain hormonal therapies. Participants will have blood collected and provide an archival sample from a previous tumor biopsy. The researchers will compare biomarkers from participants who responded well to treatment to those who responded poorly in order to answer the research question.
The group in the trial
- Men with progressive metastatic castration resistant prostate cancer (mCRPC)
Men with progressive metastatic castration resistant prostate cancer (mCRPC) and starting standard of care therapy with a second androgen receptor (AR) inhibitor (typically enzalutamide or abiraterone acetate) will have blood collected for circulating tumor cell (CTC) assessments and other research assessments at baseline, 12 weeks and upon disease progression.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Validation of a Circulating Tumor Cell AR Therapy Resistance Assay in Men With Metastatic Castration Resistant Prostate Cancer (ARCTIC)
- Plain-language title
- Blood cell markers to predict response in metastatic castration resistant prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026